Continuous Manufacturing in Pharmaceuticals: Implications for the Generics Market, 2017-2024 -

DUBLIN--()--The "Continuous Manufacturing in Pharmaceuticals: Implications for the Generics Market" report has been added to's offering.

Report Coverage

  • A market outlook of Continuous Manufacturing (CM) in pharmaceuticals and bio-pharmaceuticals market
  • Analyses of global CM market trends, with data from 2017-2018, estimates for 2019 and projections of CAGRs through 2024
  • Information on the role of U.S. FDA in the growing popularity of CM, the changing mindset of the pharmaceutical sector, and other factors that are impacting the adoption of CM in the pharmaceuticals sector
  • A look at generic drugs market and future trends for CM
  • Patent analysis highlighting the innovation in CM

The pharmaceutical market is one of the fastest-growing markets in the world, and there is a burgeoning demand for innovative therapies and affordable drugs. Despite the boom in pharmaceutical growth, pharmaceutical manufacturers are burdened with pricing pressures, demand for better quality and the need for improved productivity. The traditional batch method of manufacturing, though still the favored method for producing drugs, is losing its charm.

In continuous manufacturing, products are continuously produced with greater accuracy and reliability. This method has been adopted for the manufacture of automobiles and consumer products with great success. Continuous manufacturing's advantages of speed, cost savings, and improved quality are attractive to pharmaceutical manufacturers.

The drive to incorporate digitization or attune processes to Industry 4.0 is another factor driving the trend towards continuous manufacturing, as it is highly compatible with automation. Industry 4.0 is being regarded as the fourth industrial revolution, wherein all the machines, devices, sensors, and people are connected with each other via the Internet of Things (IoT), revolutionizing the way manufacturing is carried out.

Key Topics Covered

Chapter 1 Technology Highlights and Market Outlook

  • What is Continuous Manufacturing?
  • How is CM Beneficial to the Pharmaceutical Industry?
  • What is the Status of Continuous Bioprocessing?
  • Industry Examples
  • What is FDA's Role in the Growing Popularity of CM?
  • What Other Factors Are Driving the Adoption of CM?
  • Growing Demand for Drugs
  • Desire to Reduce Costs and Increase Product Quality
  • PAT Guidance
  • Drive Toward Digitalization
  • Partnerships and Collaborations
  • Innovation in Technology
  • Which Pharmaceuticals Are Still Reluctant to Introduce CM at Full Scale?
  • Traditional Mindset
  • Cost of Transformation
  • CM Not Suitable for All Product Types
  • Requirement of Skilled Personnel
  • Lack of Experience and Data
  • Generics Drug Market and CM
  • Generic Drugs Compete with the Branded Drugs
  • Manufacturing Process is the Deciding Factor
  • Lurking Issues for the Generics Sector
  • Is Continuous Manufacturing the Solution for Generics Manufacturers?
  • Latest FDA Guidance-What is the Future?
  • Market Outlook for CM in Pharmaceuticals and Biopharmaceuticals
  • Market by Type
  • Market by End User
  • Market by Region
  • Brief Patent Analysis Highlighting Innovation in CM
  • Patents by Year
  • Patents by Type
  • Patents by Assignee
  • Major Players in the CM Market
  • Market Shares
  • Information Sources
  • Methodology

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900